- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07342478
cBTKi 사전 치료 R/R CLL/SLL에서의 Rocbrutinib 대 Pirtobrutinib (3상)
코발렌트 BTK 억제제(cBTKi) 사전 치료를 받은 재발성 또는 불응성 만성 림프구성 백혈병(CLL)/소림프구성 림프종(SLL) 대상자에서 Rocbrutinib(LP-168) 대 Pirtobrutinib의 3상 오픈라벨, 무작위, 다기관 연구
This is a Phase 3, randomized, open-label, multicenter study comparing rocbrutinib (LP-168) versus pirtobrutinib in adult participants with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received a covalent Bruton's tyrosine kinase inhibitor (cBTKi). Approximately 306 participants will be randomized 1:1 to receive rocbrutinib 200 mg orally once daily or pirtobrutinib 200 mg orally once daily, administered continuously in 28-day cycles until disease progression, unacceptable toxicity, withdrawal of consent, or other discontinuation criteria are met. Randomization will be stratified by presence of del(17p)/TP53 mutation (yes/no), reason for discontinuation of prior cBTKi therapy (toxicity vs disease progression), prior exposure to a BCL2 inhibitor (yes/no), and region (United States/China/rest of world). The primary endpoint is progression-free survival (PFS) assessed by an independent review committee (IRC) using iwCLL 2018 criteria for CLL and Lugano 2014 criteria for SLL. Key secondary objectives include overall survival, overall response rate, time-to-event outcomes, and safety/tolerability; exploratory objectives include health-related quality of life and biomarker assessments.
연구 개요
상태
개입 / 치료
상세 설명
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are indolent B-cell malignancies characterized by accumulation of mature but dysfunctional lymphocytes. Covalent Bruton's tyrosine kinase inhibitors (cBTKis) have substantially improved outcomes for patients with CLL/SLL; however, disease progression on cBTKi therapy or intolerance leading to treatment discontinuation remains an important clinical challenge. Patients who discontinue cBTKi therapy due to progression have limited therapeutic options and may experience poor outcomes. Therefore, effective and well-tolerated therapies are needed for participants with relapsed or refractory (R/R) CLL/SLL who have previously received a covalent BTK inhibitor.
Rocbrutinib (LP-168) is a selective next-generation inhibitor of BTK, that can irreversibly inhibit WT BTK, and reversibly inhibit C481 mutated BTK, with activity against known resistance mutations for non-covalent BTKi, under investigation for the treatment of CLL/SLL. Pirtobrutinib is an oral BTK inhibitor with regulatory approval for adults with R/R CLL/SLL who have previously received a covalent BTK inhibitor (cBTKi). This Phase 3 study is designed to compare the efficacy and safety of rocbrutinib versus pirtobrutinib in adult participants with cBTKi-pretreated R/R CLL/SLL.
This is a Phase 3, randomized, open-label, multicenter study conducted at approximately 100 sites globally. Approximately 306 participants will be randomized in a 1:1 ratio to receive rocbrutinib (LP-168) or pirtobrutinib. Eligible participants are adults with confirmed R/R CLL or SLL who require therapy and have received prior treatment with a cBTKi. Participants may have received additional prior systemic therapies, including prior exposure to a BCL2 inhibitor. Key exclusion criteria include central nervous system involvement by CLL/SLL and clinically significant cardiovascular conditions, including uncontrolled arrhythmias and clinically relevant QTc prolongation.
Participants randomized to the investigational arm will receive rocbrutinib 200 mg orally once daily. Participants randomized to the active comparator arm will receive pirtobrutinib 200 mg orally once daily. Study treatments will be administered continuously in 28-day cycles until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-defined discontinuation criteria. Crossover between treatment arms is not permitted.
Randomization will be stratified based on prognostic and treatment-history factors, including: (1) del(17p) and/or TP53 mutation status, (2) reason for discontinuation of prior cBTKi therapy, (3) prior exposure to a BCL2 inhibitor, and (4) geographic region.
The primary endpoint is progression-free survival (PFS). PFS will be assessed by an independent review committee (IRC) to provide objective evaluation of disease status. Response and progression for participants with CLL will be assessed according to iwCLL 2018 criteria, while participants with SLL will be assessed using Lugano 2014 criteria.
Key secondary efficacy endpoints include overall survival (OS), overall response rate (ORR), duration of response (DOR), time to next treatment (TTNT), and event-free survival (EFS). Additional secondary objectives include characterization of the safety and tolerability of rocbrutinib relative to pirtobrutinib. Safety will be assessed through evaluation of adverse events (AEs), serious adverse events (SAEs), adverse events of special interest, deaths, physical examinations, vital signs, electrocardiograms, and clinical laboratory assessments. AEs will be graded using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. In addition, population pharmacokinetics will be evaluated to characterize exposure-response relationships.
Exploratory objectives include evaluation of patient-reported outcomes and health-related quality of life, as well as biomarker assessments aimed at characterizing disease biology, mechanisms of response and resistance, and potential predictors of clinical benefit.
연구 유형
등록 (추정된)
단계
- 3단계
연락처 및 위치
연구 연락처
- 이름: Anna Y Chen, M.D., Ph.D.
- 전화번호: 1-206-335-3820
- 이메일: ROCKET-CLL@newavepharma.com
연구 연락처 백업
- 이름: Stephen Anthony, D.O.
- 전화번호: 1-509-847-5646
- 이메일: ROCKET-CLL@newavepharma.com
연구 장소
-
-
Illinois
-
Skokie, Illinois, 미국, 60077
- 모병
- Orchard Healthcare Research
-
-
Maryland
-
Bethesda, Maryland, 미국, 20817
- 모병
- The Center for Cancer and Blood Disorders-Bethesda
-
-
Nevada
-
Las Vegas, Nevada, 미국, 89102
- 모병
- Optum Medical Group (Rhodes) P.C.
-
-
North Carolina
-
Durham, North Carolina, 미국, 27705
- 모병
- Duke Adult Blood and Marrow Clinic
-
-
Ohio
-
Columbus, Ohio, 미국, 43210
- 아직 모집하지 않음
- OSU Comprehensive Cancer Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, 미국, 15213
- 모병
- UPMC Hillman Cancer Center
-
-
Washington
-
Spokane, Washington, 미국, 99208
- 모병
- Medical Oncology Associates - Spokane
-
-
-
-
-
Le Mans, 프랑스, 72037
- 모병
- Centre Hospitalier Le Mans
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Age ≥18 years;
- Histologically confirmed CLL/SLL iwCLL 2018;
- Relapsed or refractory disease requiring treatment;
- Previously treated with prior lines of therapy including a covalent BTK inhibitor;
- Measurable disease;
- ECOG 0-2;
- Adequate marrow, hepatic, and renal function;
- TP53 mutation status confirmed by NGS;
- 17p deletion status confirmed by FISH;
Exclusion Criteria:
- Prior ncBTKi or BTK degraders;
- Richter's transformation;
- Confirmed prolymphocytic leukemia;
- Uncontrolled comorbidities or infections;
- Known CNS involvement by CLL/SLL;
- Prior malignancy requiring active treatment (except certain adequately treated cancers) per protocol;
- Pregnancy or breastfeeding;
- Concomitant medications or conditions prohibited by protocol (e.g., strong drug-drug interaction risk);
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Rocbrutinib
200mg daily |
The new generation, highly potent, ultra-selective BTK inhibitor with covalent and non-covalent dual binding mechanism, targeting both WT BTK and mutant BTK |
|
활성 비교기: Pirtobrutinib
200mg daily |
Pirtobrutinib is a non-covalent BTK inhibitor. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
PFS assessed by IRC
기간: From randomization until disease progression or death from any cause, assessed up to approximately 4 years.
|
Progression-Free Survival assessed by independent review committee. PFS is defined as the time from the date of randomization to disease progression or death from any cause, whichever occurs first. Those who do not experience disease progression or death at the time of analysis are censored according to the last evaluation time point. |
From randomization until disease progression or death from any cause, assessed up to approximately 4 years.
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
OS
기간: From randomization until death from any cause, assessed up to approximately 4 years
|
Overall survival is defined as the time from the date of randomization to death from any cause. Those who did not die during the analysis were censored according to the last date the subject is known to be alive. |
From randomization until death from any cause, assessed up to approximately 4 years
|
|
PFS assessed by INV
기간: From randomization until disease progression or death from any cause, assessed up to approximately 4 years.
|
Progression free survival assessed by investigator |
From randomization until disease progression or death from any cause, assessed up to approximately 4 years.
|
|
ORR
기간: From randomization until disease progression, assessed up to approximately 4 years
|
Overall response rate |
From randomization until disease progression, assessed up to approximately 4 years
|
|
DOR
기간: From first documented response until disease progression or death, assessed up to approximately 4 years
|
Duration of response |
From first documented response until disease progression or death, assessed up to approximately 4 years
|
|
TTNT
기간: From randomization to start of next anti-CLL/SLL treatment, assessed up to approximately 4 years.
|
Time to next treatment |
From randomization to start of next anti-CLL/SLL treatment, assessed up to approximately 4 years.
|
|
EFS
기간: From randomization until an event occurs, assessed up to approximately 4 years.
|
Event free survival |
From randomization until an event occurs, assessed up to approximately 4 years.
|
|
Safety and tolerability
기간: From first dose through 30 days after the last dose of study treatment (up to approximately 4 years)
|
Safety and tolerability will be assessed by the incidence, severity, and relationship of adverse events (AEs) and serious adverse events (SAEs), including deaths; adverse events leading to dose modification or discontinuation; and changes in clinical laboratory parameters. Adverse events will be graded per NCI CTCAE v5.0, with specific monitoring for clinically significant cardiac arrhythmias and bleeding events. |
From first dose through 30 days after the last dose of study treatment (up to approximately 4 years)
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Health related quality of Life
기간: From baseline through end of treatment and follow-up, assessed up to approximately 4 years.
|
Health-related quality of life (HRQoL) will be assessed using validated patient-reported outcome (PRO) questionnaires to evaluate participants' functioning and symptoms over time. HRQoL endpoints will include change from baseline in overall health status and selected symptom and function domains. For the Global Health Status/QoL and functional scales, higher scores indicate better quality of life and functioning. For symptom scales/items, higher scores indicate greater symptom burden (worse symptoms). |
From baseline through end of treatment and follow-up, assessed up to approximately 4 years.
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
- 오픈 라벨
- 무작위
- 재발성 또는 불응성
- CLL
- 3단계
- PFS
- 만성림프구성백혈병
- SLL
- BTK 억제제
- 소림프구성림프종
- 무진행 생존
- 글로벌
- 피르토브루티닙
- TP53 돌연변이
- CLL/SLL
- LP-168
- Jaypirca
- 로크브루티닙
- 공유 결합 BTK 억제제 사전 치료
- cBTKi 사전 치료된 / cBTKi 노출된
- 비공유 결합 BTK 억제제
- 차세대 BTKi
- 이중 결합 BTKi
- 4세대 BTKi
- 매일 1회 경구
- 독립 검토 위원회
- IRC 평가
- iwCLL 2018
- 루가노 2014
- del(17p)
- 이전 BCL2 억제제 노출
- 이전 BTKi 중단 이유 (진행 vs 내약성)
추가 관련 MeSH 약관
기타 연구 ID 번호
- LP-168-US-CLL301
- ROCKET-CLL (기타 식별자: Newave Pharmaceutical Inc.)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .